MDx/CDx Focus: Cellceutix Planning Phase I Study for Kevetrin; Labceutics Launches EU Lab Network
June 27, 2012
MDx/CDx Focus: Cellceutix Planning Phase I Study for Kevetrin; Labceutics Launches EU Lab Network
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Labceutics, Asuragen Conducting BCR-ABL Quality Assurance Study Among European Labs
March 13, 2013 / Pharmacogenomics Reporter - With Decode Purchase, Amgen Gains Genetics Expertise, Consumers Lose DTC Testing Option
December 12, 2012 / Pharmacogenomics Reporter - Dx Assays Launches Fee-for-Service CDx Development Initiative Giving Pharma More Control
November 2, 2012 / Pharmacogenomics Reporter - Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 22, 2013 / Pharmacogenomics Reporter